Payment overview · 2025
General Payments
$405.36
19 reported records · 11 companies
Healthcare provider profile · identity verified
Sunil J Abraham, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · VICTORVILLE, CA · NPI 1013161306
Verified facts
What the public records show
CMS Open Payments records show Sunil J Abraham, M.D. received $405.36 in general payments during 2025 across 19 reported records.
PFIZER INC. accounted for 19.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 199 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 199 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $79.24 | 19.6% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $75.09 | 18.5% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $52.90 | 13.1% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $41.60 | 10.3% | 2 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $35.28 | 8.7% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $27.91 | 6.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $22.95 | 5.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.44 | 4.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $18.74 | 4.6% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.80 | 4.1% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $15.41 | 3.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $405.36 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $58.58 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $58.58 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $52.91 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $52.90 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $41.60 | 2 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $35.28 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $27.91 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $22.95 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $22.18 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $20.66 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $20.66 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $20.66 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $19.44 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.74 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.80 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $15.41 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 199 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
199 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
199 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
116 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 471 | 144 |
| Omeprazole | Omeprazole | 352 | 81 |
| Amlodipine Besylate | Amlodipine Besylate | 346 | 88 |
| Levothyroxine Sodium | Levothyroxine Sodium | 336 | 76 |
| Lisinopril | Lisinopril | 332 | 94 |
| Metformin Hcl | Metformin Hcl | 328 | 88 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 305 | 49 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 303 | 72 |
| Gabapentin | Gabapentin | 303 | 57 |
| Losartan Potassium | Losartan Potassium | 233 | 56 |
| Ibuprofen | Ibuprofen | 224 | 54 |
| Jardiance | Empagliflozin | 199 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 179 | 48 |
| Simvastatin | Simvastatin | 173 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 160 | 35 |
| Furosemide | Furosemide | 155 | 33 |
| Trazodone Hcl | Trazodone Hcl | 145 | 23 |
| Potassium Chloride | Potassium Chloride | 133 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 130 | 35 |
| Eliquis | Apixaban | 116 | 24 |
| Clonidine Hcl | Clonidine Hcl | 110 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 110 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 108 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 107 | 22 |
| Alendronate Sodium | Alendronate Sodium | 100 | 33 |
| Alprazolam | Alprazolam | 92 | 16 |
| Ozempic | Semaglutide | 85 | 12 |
| Atenolol | Atenolol | 84 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 84 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 74 | 25 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 73 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 72 | 17 |
| Benazepril Hcl | Benazepril Hcl | 70 | 13 |
| Tramadol Hcl | Tramadol Hcl | 69 | 21 |
| Baclofen | Baclofen | 67 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 67 | 24 |
| Glipizide Er | Glipizide | 64 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 62 | 12 |
| Januvia | Sitagliptin Phosphate | 58 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 57 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 55 | 17 |
| Famotidine | Famotidine | 50 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 50 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 47 | suppressed |
| Lactulose | Lactulose | 46 | 17 |
| Naproxen | Naproxen | 46 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 46 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 46 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 45 | suppressed |
| Glipizide | Glipizide | 45 | 14 |
| Montelukast Sodium | Montelukast Sodium | 45 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 44 | suppressed |
| Allopurinol | Allopurinol | 43 | suppressed |
| Carvedilol | Carvedilol | 43 | 14 |
| Metformin Hcl Er | Metformin Hcl | 43 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 42 | suppressed |
| Clonazepam | Clonazepam | 41 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 41 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 40 | 29 |
| Azithromycin | Azithromycin | 35 | 23 |
| Paroxetine Hcl | Paroxetine Hcl | 35 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 34 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 33 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 33 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 32 | 13 |
| Enalapril Maleate | Enalapril Maleate | 32 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 32 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 31 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Meloxicam | Meloxicam | 30 | suppressed |
| Methocarbamol | Methocarbamol | 30 | suppressed |
| Finasteride | Finasteride | 29 | suppressed |
| Lidocaine | Lidocaine | 28 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 28 | suppressed |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Prednisone | Prednisone | 26 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 26 | suppressed |
| Lovastatin | Lovastatin | 25 | suppressed |
| Clotrimazole | Clotrimazole | 24 | suppressed |
| Mupirocin | Mupirocin | 24 | 11 |
| Valacyclovir | Valacyclovir Hcl | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | suppressed |
| Cephalexin | Cephalexin | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Felodipine Er | Felodipine | 20 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 20 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 20 | suppressed |
| Carisoprodol | Carisoprodol | 19 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Calcitriol | Calcitriol | 18 | suppressed |
| Cilostazol | Cilostazol | 18 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 18 | suppressed |
| Insulin Lispro | Insulin Lispro | 17 | suppressed |
| Lorazepam | Lorazepam | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | suppressed |
| Ubrelvy | Ubrogepant | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Invokana | Canagliflozin | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Ssd | Silver Sulfadiazine | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Ramelteon | Ramelteon | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Etodolac | Etodolac | 14 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 11 |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $405.36 · 19 records | PFIZER INC. | ABRYSVO, AIRSUPRA, BREZTRI, COMIRNATY, Cologuard Collection Kit, JARDIANCE, JOURNAVX, Kerendia, MOUNJARO, NURTEC ODT, Ohtuvayre, PREVNAR 20, WAKIX, XIFAXAN, ZAVZPRET, ZORYVE | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error